VIB spin-off MRM Health reports positive preclinical results in non-alcoholic fatty liver disease

June 7, 2022

MRM Health is a VIB spin-off founded in 2020 by Sam Possemiers in a joint venture with VIB. Using a 9-strain bacterial consortium, MRM Health’s laboratories led by Dr. Salvador Augustin and Dr. Maria Martell of the University Hospital of Vall d’Hebron were able to slow down disease progression in Non-Alcoholic Fatty Liver Disease (NAFLD). Preclinical results show that a live bacterial consortium of 9 rationally selected gut commensal strains were able to improve portal hypertension, insulin signaling, and NAFLD activity score. Additionally, the consortium helped prevent fibrosis development in two different in vivo disease models of Non-Alcoholic Steatohepatitis (NASH), improving endothelial functions and rebalancing the gut microbiome.

Lies Vanneste

Investor Relations Manager, VIB

Latest stories

New tool makes gene regulation easier to study—and tweak

Leuven, 2 April 2026 - Understanding how genes are switched on and off in specific cell types remains one of biology’s central challenges. While AI has made major progress in decoding the regulatory logic of DNA, applying these approaches across datasets, tissues, and species has remained difficult. In a new Nature Methods paper, a research team led by Prof. Stein Aerts (VIB & KU Leuven) presents CREsted, a software package that enables both the analysis and design of gene regulatory elements in a systematic and scalable way.

press.vib.be

Blocking lipid production in healthy lung cells can reduce lung metastasis

Leuven, 17 March 2026 - Scientists from the VIB–KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, have discovered how cancer cells can exploit healthy lung cells to support metastatic tumor growth in the lungs. In two complementary studies published in Nature Cell Biology and Cancer Discovery, they show that tumors use lipids produced by lung cells as signals, and that decreasing the lipid production of lung cells can decrease metastasis. The findings point to new therapeutic strategies that target lung cell lipid production, rather than cancer cells themselves, which may also help refine patient selection for ongoing clinical trials targeting this pathway.

press.vib.be

Researchers identify major genetic risk factor for rare form of dementia

Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.

press.vib.be

VIB spin-off MRM Health reports positive preclinical results in non-alcoholic fatty liver disease

Lies Vanneste

Share

Latest stories

About VIB Press

Contact